GlassScriptPhysician profile
Michael A Flores
NPI 1215362553
$3,300.41
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,586 · 2022: $1,139 · 2023: $575.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $575.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $575.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $735.12 | 2021-2023 | Ozempic, Rybelsus |
| Lilly USA, LLC | $601.00 | 2021-2023 | Mounjaro |
| Amgen INC. | $288.84 | 2021-2023 | Repatha, Otezla |
| Biohaven Pharmaceutical Holding Company LTD. | $194.55 | 2022 | |
| Abbvie INC. | $165.92 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $144.45 | 2021-2023 | Trulance, Xifaxan |
| Biohaven Pharmaceuticals, INC. | $129.95 | 2021 | |
| Janssen Pharmaceuticals, INC | $125.81 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $103.83 | 2021-2023 | Farxiga |
| Amarin Pharma, INC. | $102.26 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.09 | 2021-2023 | Jardiance, Tradjenta |
| Eisai INC. | $75.98 | 2021-2022 | |
| Glaxosmithkline, LLC. | $69.94 | 2021-2023 | Shingrix, Arexvy |
| Esperion Therapeutics, INC. | $57.93 | 2021 | |
| Merck Sharp & Dohme LLC | $56.75 | 2021-2023 | Steglujan, Steglatro, Belsomra |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $55.59 | 2023 | |
| Paratek Pharmaceuticals, INC. | $53.43 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $50.00 | 2022-2023 | |
| Dexcom, INC. | $32.80 | 2021-2023 | Dexcom G6 Transmitter |
| Medtronic, INC. | $29.22 | 2021 | |
| Upsher-Smith Laboratories LLC | $26.11 | 2021 | |
| Genentech USA, INC. | $24.71 | 2021 | |
| Novartis Pharmaceuticals Corporation | $22.45 | 2023 | |
| Sanofi-Aventis U.S. LLC | $21.97 | 2021 | |
| Astellas Pharma US INC | $19.58 | 2023 | Myrbetriq |
| Abbott Laboratories | $18.99 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $12.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Flores listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.